TrialPloS one2018

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

Paul H Cottu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.